enVVeno Medical Corp has 12 Schedule 13D or 13G filings on record since 2025-09-09. 3 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 9% | 1,822,500 | SCHEDULE 13G, 2025-11-19 | 2025-11-14 |
| Kingdon Capital Management, L.L.C. | 5.5% | 36,166 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Northstrive Fund II LP | 5.05% | 20,129 | SCHEDULE 13D, 2026-02-20 | 2026-02-20 |
| Perceptive Advisors LLC | 3.5% | 24,605 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Nantahala Capital Management, LLC | 3.46% | 688,940 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Braeden Lichti | 0% | 0 | SCHEDULE 13D/A, 2026-09-15 | 2026-09-11 |
Purpose of Transaction (Item 4)
Braeden Lichti
On September 11, 2026, Braeden Lichti sold all of his previously owned shares of the Issuer's Common Stock and no longer owns any shares of Common Stock. From September 11, 2026 to September 14, 2026, NorthStrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Previously, the Reporting Persons herein filed a Schedule 13D with the U.S. Securities and Exchange Commission on February 20, 2026 ("Schedule 13D"), which reported the number of shares held by each reporting person as of February 20, 2026. This Schedule 13D/A filing is the final amendment to the Schedule 13D and constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP.Item 4 of the SCHEDULE 13D/A filed 2026-09-15
Northstrive Fund II LP
As of February 10, 2026, the Reporting Persons beneficially owned 33,151 shares of Common Stock, representing 5.05% of the Issuer's issued and outstanding Common Stock. This percentage was calculated based on 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026. On February 10, 2026, neither of the Reporting Persons had control or influence intent in the Issuer. This Schedule 13D is being filed to disclose Northstrive's Fund letter to the Board of Directors of the Issuer dated February 20, 2026 (the "Board Letter"). The Board Letter includes, among other things, Northstrive's Fund recommendations to the Board to immediately halt all clinical operations and launch a formal strategic review to either return capital to shareholders or pursue a merger or reverse merger to maximize shareholder value while preserving cash and minimizing further burn and dilution. Northstrive Fund has requested to meet with the senior management of the Issuer in the Board Letter. The Board Letter is filed herein as Exhibit A. As the Board Letter indicates an intent by the Reporting Persons with a purpose or effect to potentially change or influence control of the Issuer, the Reporting Persons have deemed it appropriate to amend the Schedule 13G by filing this Schedule 13D. The Reporting Persons intend to review their investment in the Issuer on a …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-09 | Kingdon Capital Management, L.L.C. | 7.1% | SCHEDULE 13G |
| 2025-11-14 | Nantahala Capital Management, LLC | 3.46% | SCHEDULE 13G/A |
| 2025-11-19 | Thomas A. Satterfield, Jr. | 9% | SCHEDULE 13G |
| 2026-02-10 | Braeden Lichti | 5.05% | SCHEDULE 13G |
| 2026-02-10 | Braeden Lichti | 5.05% | SCHEDULE 13G |
| 2026-02-17 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-20 | Northstrive Fund II LP | 5.05% | SCHEDULE 13D |
| 2026-02-20 | Braeden Lichti | 5.05% | SCHEDULE 13D |
| 2026-05-15 | Kingdon Capital Management, L.L.C. | 5.5% | SCHEDULE 13G/A |
| 2026-05-15 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 3.5% | SCHEDULE 13G/A |
| 2026-09-15 | Braeden Lichti | 0% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for enVVeno Medical Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.